ResMed price target lowered to $240 from $250 at Stifel

Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey responses from 47 U.S. Sleep Specialists, the firm tells investors that its physician feedback highlights several future challenges for the CPAP market that likely emerge from the increasing prominence of GLP-1s. The overall takeaway from the checks is “one of caution,” adds the analyst, who notes the the firm’s FY27 EPS view is now the “Street-low.”